Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

• Market Cap: ₹96.85B
• Dividend Yield: 3.17%
• Average Volume (3M): 346.00
• Price to Earnings (P/E): 31.6
• Beta (1Y): 0.49
• Revenue Growth: 3.01%
• EPS Growth: 22.98%
• Country: IN
• Employees: 1,336
• Sector: Consumer Goods
• Sector Strength: N/A
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 53.34
• Shares Outstanding: 16,599,382
• 10 Day Avg. Volume: 302
• 30 Day Avg. Volume: 346
• PEG Ratio: 1.37
• Price to Book (P/B): 15.96
• Price to Sales (P/S): 7.03
• P/FCF Ratio: 51.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ₹6,857.00 ▲(10.32% Upside)

Procter & Gamble Health Ltd. demonstrates strong financial performance with robust profitability and a solid balance sheet, contributing significantly to the overall score. The technical analysis indicates mixed signals with short-term bearish momentum but a long-term bullish trend. The valuation is slightly high, reflecting growth expectations, but the attractive dividend yield provides a buffer. The absence of earnings call data and corporate events does not impact the score.

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Health Ltd. (PGHL) is a subsidiary of Procter & Gamble Company, specializing in health and wellness products. The company operates within the healthcare sector, focusing on a variety of consumer health products, including over-the-counter medications, dietary supplements, and oral health products. PGHL aims to improve consumer health and well-being through its scientifically backed and trusted product offerings.

How the Company Makes Money

PGHL generates revenue primarily through the sale of its health-related products, which are marketed under well-known brands. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include prescription and over-the-counter medications, vitamins and supplements, and oral hygiene products. Additionally, PGHL benefits from strategic partnerships with healthcare providers and organizations that enhance product visibility and consumer trust. The company's strong brand equity and continued investment in research and development also contribute significantly to its earnings by ensuring a steady pipeline of innovative health solutions.

Procter & Gamble Health Ltd. Financial Statement Overview

Summary

Procter & Gamble Health Ltd. exhibits a strong financial position across all verticals. The income statement reflects robust profitability and growth, while the balance sheet indicates excellent financial stability with low leverage. The cash flow statement is positive, with strong cash generation capabilities. The company is well-positioned for future growth, though there is room for improvement in cost management and operational efficiency.

Income Statement

Procter & Gamble Health Ltd. demonstrates strong profitability with a consistent increase in net profit margin and EBIT margin over the years. The company has shown a healthy revenue growth rate of 7.42% in the most recent year, indicating robust sales performance. However, the gross profit margin has declined slightly, suggesting increased cost pressures. Overall, the income statement reflects a solid financial performance with room for improvement in cost management.

Balance Sheet

The balance sheet of Procter & Gamble Health Ltd. is very strong, characterized by a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial risk. The return on equity is impressive at 58.21%, showcasing efficient use of shareholder funds to generate profits. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet is robust, with excellent financial stability and low risk.

Cash Flow

The cash flow statement shows a positive trajectory with strong free cash flow to net income ratio of 0.95, indicating efficient cash generation relative to net income. The operating cash flow to net income ratio is slightly lower at 0.82, suggesting room for improvement in operational efficiency. The free cash flow growth rate is exceptionally high, but this is due to a low base effect. Overall, the cash flow position is solid, with potential for enhanced operational cash flow management.

Breakdown	TTM	Dec 2025	Dec 2018	Dec 2017	Dec 2016
Income Statement
Total Revenue	12.43B	12.18B	8.49B	11.04B	9.93B
Gross Profit	8.96B	8.69B	5.78B	6.58B	5.76B
EBITDA	3.43B	3.62B	1.96B	2.19B	1.57B
Net Income	2.35B	2.51B	8.39B	939.10M	758.90M
Balance Sheet
Total Assets	7.94B	7.94B	17.59B	9.91B	8.83B
Cash, Cash Equivalents and Short-Term Investments	2.06B	1.89B	12.43B	3.48B	3.07B
Total Debt	76.20M	76.20M	65.30M	67.10M	0.00
Total Liabilities	2.57B	2.57B	2.19B	2.58B	2.37B
Stockholders Equity	5.37B	5.37B	15.40B	7.33B	6.45B
Cash Flow
Free Cash Flow	459.90M	1.67B	-1.57B	233.60M	753.90M
Operating Cash Flow	492.20M	1.76B	-1.30B	536.60M	1.07B
Investing Cash Flow	-500.00K	24.40M	12.70B	-476.30M	-749.70M
Financing Cash Flow	-1.34B	-2.35B	-300.50M	-219.80M	-149.80M

Procter & Gamble Health Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6215.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Negative. The current price of 6215.8 is above the 20-day moving average (MA) of 6126.90, below the 50-day MA of 6244.12, and above the 200-day MA of 5678.75, indicating a neutral trend. The MACD of -64.54 indicates Positive momentum. The RSI at 29.34 is Positive, neither overbought nor oversold. The STOCH value of 14.72 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGHL	73 Outperform	₹96.85B	31.57	―	3.17%	3.01%	22.98%
ZYDUSWELL	73 Outperform	₹143.17B	56.50	―	0.27%	14.55%	-20.61%
SURYAROSNI	71 Outperform	₹65.99B	22.92	―	1.41%	-8.69%	-20.94%
SYMPHONY	70 Outperform	₹64.62B	49.70	―	1.38%	-19.72%	-44.03%
JYOTHYLAB	68 Neutral	₹115.87B	31.70	―	1.12%	1.59%	-2.52%
EVEREADY	62 Neutral	₹27.12B	32.55	―	0.41%	7.37%	-39.19%
Sector *	57 Neutral	$3.13B	9.23	-34.32%	3.14%	-25.56%	-353.61%

Procter & Gamble Health Ltd. Corporate Events

Procter & Gamble Health Limited Supports ‘Saksham Niveshak’ Campaign to Aid Shareholders

Procter & Gamble Health Limited has announced its participation in the ‘Saksham Niveshak’ campaign, initiated by the Investor Education and Protection Fund Authority under the Ministry of Corporate Affairs. This 100-day campaign aims to assist shareholders in claiming unpaid or unclaimed dividends by updating their KYC details. The company is urging shareholders to update their contact and bank details to facilitate the receipt of dividends and ensure the security of their shares. This initiative underscores the company’s dedication to shareholder engagement and compliance with regulatory requirements, potentially enhancing shareholder satisfaction and trust.